Abstract 29
The neutropenic, murine thigh infection model was used to define the PK/PD index linked to 30 efficacy of iclaprim against S. aureus ATCC 29213 and S. pneumoniae ATCC 10813. The 24h 31 AUC/MIC index was most closely linked to efficacy for S. aureus (R 2 =0.65), while both the 24h 32 AUC/MIC and the %T>MIC were both strongly associated with effect (R 2 =0.86 for both 33 parameters) for S. pneumoniae. 
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Preclinical PK/PD studies using murine infection models have become standard in the 53 development of antimicrobials to aid in selection of dosing regimens for clinical trials (1-3). 54
These studies have been challenging for the dihydrofolate reductase inhibitors (DHFRi) as high 55 levels of thymidine in rodents antagonized drug activity (4). As such, use of these models to 56 define the magnitude of the linked PK/PD index would greatly overestimate the drug exposure 57 needed for efficacy in humans, which have thymidine concentrations 100-fold lower than rodents 58 (4). Certain bacteria, including S. aureus, have the capability of uptake of exogenous thymidine 59 and its conversion into thymidylate by thymidine kinase, which interferes with the antimicrobial 60 activity of the diaminopyridimide drug TMP in vitro (5). However, it should still be possible to 61 use these infection models to define the optimal PK/PD index. Iclaprim is a novel, broad-62 spectrum, DHRFi (6). The present studies were designed to determine the PK/PD driver for 63 icalprim. Studies were also performed to investigate the impact of mouse and human serum on 64 in vitro activity of iclaprim. 65
We utilized the neutropenic, murine thigh infection model (CD-1 mice) for both 66 pharmacokinetic and pharmacodynamics studies (2). A strain of S. aureus (ATCC 29213) and S. 67 pneumoniae (ATCC 10813) were used. In vitro susceptibility testing was performed twice in 68 duplicate using CLSI methodology; modal MIC values are reported. In broth, the MIC values 69 were 0.12 and 0.06 mg/L, for S. aureus and S. pneumoniae, respectively. The MIC values for 70 iclaprim were significantly higher in serum than in broth for both S. aureus and S. pneumoniae; 71 MIC values were also markedly higher in mouse serum than in human serum. In 95% mouse 72 serum, the MIC values were >80 and 80 mg/L, for S. aureus and S. pneumoniae, respectively. 73
The MIC values of iclaprim was 10 times higher in 95% human serum than observed in broth 74 The organism burden in the thighs of mice at the start of pharmacokinetic and 79 pharmacodynamics studies was 10 6.4-7.8 CFU/thigh. Single-dose plasma pharmacokinetics were 80 performed following subcutaneous doses of iclaprim ranging from 20 to 320 mg/kg. Groups of 81 six mice were sampled seven times at 0.25 to 120 minute intervals over six hours. Iclaprim 82 concentrations were determined using a bioassay using Bacillus subtilus ATCC 6142 as the 83 assay organism. The lower limit of detection for this assay was 0.5 ug/ml and the coefficient of 84 variation was less than 10%. Protein binding was determined by ultrafiltration. The beta-85 elimination half-life, determined by linear least-squares regression (2, 7), was 9.85 minutes as 86 was similar over the dose range. Protein binding of iclaprim was 89% over the concentration 87
range. 88
Efficacy studies utilized five total doses of iclaprim ranging from 80 to 1280 89 mg/kg/8hours and 40 to 2560 mg/kg/8hours total dose over the treatment period for S. 90 pneumoniae ATCC 10813 and S. aureus ATCC 29213, respectively. These dose-ranging doses 91 were chosen based on other iclaprim animal infection models and to establish which dose works 92 best in this model (unpublished data). These dose levels were fractionated using four dosing 93 intervals (every 1, 2, 4, or 8 hours). We utilized an 8 hour treatment duration, as preliminary 94 studies using a 24 hour treatment duration demonstrated limited treatment efficacy due to 95 inhibition of drug (presumably due to elevated thymidine concentrations in mice). The dose 96 response relationships for iclaprim against S. pneumoniae ATCC 10813 and S. aureus ATCC 97 29213 at various dosing frequencies are shown in Figure 1A (Figure 2A ). There was no order by dosing interval that suggested AUC/MIC was better. 106
These data are consistent with historical PK/PD data of AUC/MIC and %T/MIC correlating best 107 with trimethoprim efficacy against S. pneumoniae tested in in normal mice (unpublished data). 108
The important task of identifying the PK/PD magnitude is not possible in this model with 109 clinical isolates. It may be possible to define the PK/PD target using strains that have been 110 genetically modified to thymidine-kinase deficient isolates (8). In the absence of these more 111 laborious studies it seems that in vitro PK/PD target analysis will be most fruitful. Specifically, 112 conducting experiment using in vitro infection models to determine PK/PD targets for efficacy, 113 and then using these targets together with a population PK model, and Monte Carlo Simulation 114 to conduct PK/PD target attainment analyses to support dose selection. 
